Mexitory (Atorvastatin)

Atorvastatin inhibits the enzyme HMG‑CoA reductase, the rate‑limiting step in hepatic cholesterol synthesis. This reduces intracellular cholesterol, leading to increased expression of LDL receptors on liver cells and enhanced clearance of LDL cholesterol from the bloodstream.

The specific dose of Mexitory is determined by the prescribing clinician based on the patient’s lipid profile, cardiovascular risk factors, age, renal and hepatic function, and any concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s recommendation.

Safety of atorvastatin in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Mexitory product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Atorvastatin, the active ingredient in Mexitory, is a high‑potency HMG‑CoA reductase inhibitor with a long half‑life, allowing flexible dosing. Compared with lower‑intensity statins, it typically achieves greater reductions in LDL‑cholesterol, but individual response and tolerability may vary, so clinicians choose the most appropriate statin based on patient factors.

Mexitory should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and sources of heat to maintain its stability and potency throughout its shelf life.

Mexitory is taken orally, usually once daily, with or without food, as directed by the prescribing healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious adverse events linked to atorvastatin include rhabdomyolysis (severe muscle breakdown), acute liver injury, and severe hypersensitivity reactions. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of an allergic reaction to their clinician.

Mexitory is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to atorvastatin or any excipients, and in patients taking contraindicated medications such as strong CYP3A4 inhibitors. Pregnant or nursing women should avoid use unless clearly indicated.